NASDAQ: SRPTSarepta Therapeutics Inc Stock
$16.85+0.83 (+5.18%)
Updated Jun 26, 2026
SRPT Price
$16.85
Fair Value Price
N/A
Market Cap
$1.78B
52 Week Low
$10.42
52 Week High
$25.32
P/E
28.08x
P/B
1.18x
P/S
1.05x
PEG
12.71x
Dividend Yield
N/A
Revenue
$2.18B
Earnings
$65.06M
Gross Margin
62.9%
Operating Margin
1.12%
Profit Margin
3%
Debt to Equity
1.11
Operating Cash Flow
$175M
Beta
1.07
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SRPT Overview
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SRPT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SRPT news, forecast changes, insider trades & much more!
SRPT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SRPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SRPT ($16.85) is trading above its intrinsic value of $3.65, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SRPT is poor value based on its earnings relative to its share price (28.08x), compared to the US market average (12.39x)
P/E vs Market Valuation
SRPT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SRPT due diligence checks available for Premium users.
Valuation
SRPT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.08x
Industry
16.27x
Market
12.39x
SRPT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SRPT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SRPT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
5.34x
SRPT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SRPT price to earnings growth (PEG)
For valuing profitable companies with growth potential
SRPT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SRPT's financial health
Profit margin
Revenue
$730.8M
Net Income
$331.0M
Profit Margin
45.3%
SRPT's Earnings (EBIT) of $24.47M... subscribe to Premium to read more.
Interest Coverage Financials
SRPT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.2B
Liabilities
$1.7B
Debt to equity
1.11
SRPT's short-term assets ($2.31B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRPT's short-term assets ($2.31B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRPT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SRPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$202.7M
Investing
-$134.4M
Financing
$241.0k
SRPT's operating cash flow ($175.28M)... subscribe to Premium to read more.
Debt Coverage Financials
SRPT vs Biotech Stocks
Sarepta Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.